Fig. 3: DOT cells exhibit compromised cytotoxicity within CRC tumors.
a, Schematic representation of the experimental approach to assess DOT cell phenotype upon their i.v. inoculation in intracecal SW620 tumor-bearing mice. b–e, Quantification of percentage of Vδ1 (b) and expression of immunomodulatory or checkpoint receptors (c), activation and cytotoxic receptors (d) and CD107a and intracellular markers (e) after 3 h of PMA and ionomycin stimulation (in the presence of protein translocation inhibitors) on DOT cells before infusion (n = 3 technical replicates) to mice and in blood and tumor (n = 4 mice for PD1, PD1+TIGIT+ and PD1+TIM3+; n = 5 mice for the rest), represented as a percentage of alive human CD45+CD3+Vδ1+ cells and assessed by flow cytometry. In b–e, colors represent individual mice. Data are presented as the means ± s.e.m. Data were analyzed by a one-way ANOVA with Tukey’s post hoc test. The experiment was independently performed three times with similar results.
